ReviewIntensive care medicine2020
Invasive candidiasis in critical care: challenges and future directions.
Review in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 177 citations in OpenAlex.
- Prevalence of invasive fungal infection in critically Ill patients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Development and Validation of a Risk Score for Predicting Invasive Candidiasis in Intensive Care Unit Patients by Incorporating Clinical Risk Factors and Lymphocyte Subtyping.Frontiers in cellular and infection microbiology · 2022Trial
- Clinical and Microbiological Characteristics of EarlyAntibiotics (Basel, Switzerland) · 2026Article
- Observational
- Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions.Chest · 2026Review
- Article
- Antifungal susceptibility, FKS1 gene expression, and virulence determinants of Candida albicans in pediatric and neonatal candidiasis.BMC infectious diseases · 2026Article
- Epidemiology, resistance patterns, and outcomes of candidemia acquired in Italian intensive care units: insights from the GIVITI network (2020-2024).Critical care (London, England) · 2026Observational
- Invasive fungal disease in patients with end-stage liver disease.Infectious diseases & immunity · 2026Review
- Evaluation of an Antifungal Agent Against Nakaseomyces Glabratus in the in Vivo Model Galleria Mellonella.Current microbiology · 2026Article
- CLEC3A-derived peptides exhibit broad-spectrum activity againstFrontiers in cellular and infection microbiology · 2026Article
- Effectiveness and Safety of Empirical Antifungal Strategies in Critically Ill, Non-Neutropenic Patients: A Multi-Center Observational Study.Infection and drug resistance · 2026Article
- French intensive care physicians' practices for the management of high-risk patients with invasive candidiasis: results from the multicenter INSPIRE survey.Annals of intensive care · 2026Article
- Early de-escalation of antifungal treatment in critically ill immunocompromised patients with proven or probable invasive candidiasis: A retrospective multicentre study.Annals of intensive care · 2026Article
- Fast-tracking fungal detection: a rapid flow cytometric method for the detection of yeasts in blood cultures.Frontiers in microbiology · 2026Article
- Enhanced antimicrobial efficacy of a vancomycin/zinc oxide/chitosan nanocomposite via Bacillus licheniformis-mediated biomodification.Discover nano · 2025Article
- Diagnosis and management of invasive candidiasis in critically ill patients: SIAARTI multidisciplinary statement.Journal of anesthesia, analgesia and critical care · 2025Review
- Amyloid fibrils of the Als5p-derived peptide NHVirulence · 2025Article
- Omics and Multiomics-Based Diagnostics for Invasive Candidiasis: Toward Precision Medicine.Molecular & cellular proteomics : MCP · 2025Review
- Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein.Mycopathologia · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
Invasive candidiasis is the most common critical care-associated fungal infection with a crude mortality of ~ 40-55%. Important factors contributing to risk of invasive candidiasis in ICU include use of broad-spectrum antimicrobials, immunosuppressive drugs, and total parenteral nutrition alongside iatrogenic interventions which breach natural barriers to infection [vascular catheters, renal replacement therapy, extracorporeal membrane oxygenation (ECMO), surgery]. This review discusses three key challenges in this field. The first is the shift in Candida epidemiology across the globe to more resistant non-albicans species, in particular, the emergence of multi-resistant Candida glabrata and Candida auris, which pose significant treatment and infection control challenges in critical care. The second challenge lies in the timely and appropriate initiation and discontinuation of antifungal therapy. Early antifungal strategies (prophylaxis, empirical and pre-emptive) using tools such as the Candida colonisation index, clinical prediction rules and fungal non-culture-based tests have been developed: we review the evidence on implementation of these tools in critical care to aid clinical decision-making around the prescribing and cessation of antifungal therapy. The third challenge is selection of the most appropriate antifungal to use in critical care patients. While guidelines exist to aid choice, this heterogenous and complex patient group require a more tailored approach, particularly in cases of acute kidney injury, liver impairment and for patients supported by extracorporeal membrane oxygenation. We highlight key research priorities to overcome these challenges in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.